Lenvatinib for Hepatocellular Carcinoma: A Literature Review

Lenvatinib for Hepatocellular Carcinoma: A Literature Review

Lenvatinib, which is an oral multikinase inhibitor, showed non-inferiority to the sorafenib in terms of overall survival (OS) and a higher objective response rate (ORR) and better progression-free survival (PFS) in patients with hepatocellular carcinoma (HCC). A good liver function and Barcelona Cli...

Full description

Bibliographic Details
Main Authors: Takeshi Hatanaka, Atsushi Naganuma, Satoru Kakizaki
Format: Article
Language:English
Published: MDPI AG 2021-01-01
Series:Pharmaceuticals
Subjects:
lenvatinib
hepatocellular carcinoma
progression-free survival
overall survival
adverse events
post-progression treatment
Online Access:https://www.mdpi.com/1424-8247/14/1/36

Internet

https://www.mdpi.com/1424-8247/14/1/36

Similar Items